Anebulo Pharmaceuticals, Inc. (OTCMKTS:ANEB – Get Free Report)’s stock price dropped 5.5% during mid-day trading on Thursday. The company traded as low as $0.26 and last traded at $0.26. Approximately 100 shares traded hands during mid-day trading, a decline of 45% from the average session volume of 183 shares. The stock had previously closed at $0.2750.
Anebulo Pharmaceuticals Stock Performance
The firm has a market capitalization of $9.86 million, a PE ratio of -1.27 and a beta of -1.88. The company has a fifty day moving average price of $0.30 and a 200-day moving average price of $0.48.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.
Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Featured Articles
- Five stocks we like better than Anebulo Pharmaceuticals
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
